Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7783060 | 0.85 | TLR8 (0.46) | SMN1; SMN2KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL3299836 | 0.85 | SMN1; SMN2 (0.37) | SMN1; SMN2CCR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL20504690 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2CCR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL476672 | 0.79 | HASPIN (0.41) | SMN1; SMN2CCR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL476538 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL8061084 | 0.74 | LMNA (0.44) | KDM4EALDH1A1GAACNR1CNR2 | |
| SCHEMBL476677 | 0.74 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4EMEN1KMT2ATP53 | |
| SCHEMBL18000433 | 0.73 | CMA1 (0.37) | SMN1; SMN2CCR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL20505204 | 0.70 | SMN1; SMN2 (0.36) | SMN1; SMN2CCR2KDM4ETP53TSHR | |
| SCHEMBL5672286 | 0.68 | CCR2 (0.37) | SMN1; SMN2CCR2KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741363-B2 | 3-Acylindole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | F12, ECI1, NQO2 | SMN1; SMN2 2155/4885CCR2 1642/4885KDM4E 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.